Xin Sheng, Mao Jiaquan, Cui Kai, Li Qian, Chen Liang, Li Qinyu, Tu Bocheng, Liu Xiaming, Wang Tao, Wang Shaogang, Liu Jihong, Song Xiaodong, Song Wen
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China.
Front Mol Biosci. 2022 Sep 14;9:974722. doi: 10.3389/fmolb.2022.974722. eCollection 2022.
Kidney renal clear cell carcinoma (KIRC) is a heterogeneous malignant tumor with high incidence, metastasis, and mortality. The imbalance of copper homeostasis can produce cytotoxicity and cause cell damage. At the same time, copper can also induce tumor cell death and inhibit tumor transformation. The latest research found that this copper-induced cell death is different from the known cell death pathway, so it is defined as cuproptosis. We included 539 KIRC samples and 72 normal tissues from the Cancer Genome Atlas (TCGA) in our study. After identifying long non-coding RNAs (lncRNAs) significantly associated with cuproptosis, we clustered 526 KIRC samples based on the prognostic lncRNAs and obtained two different patterns (Cuproptosis.C1 and C2). C1 indicated an obviously worse prognostic outcome and possessed a higher immune score and immune cell infiltration level. Moreover, a prognosis signature (CRGscore) was constructed to effectively and accurately evaluate the overall survival (OS) of KIRC patients. There were significant differences in tumor immune microenvironment (TIME) and tumor mutation burden (TMB) between CRGscore-defined groups. CRGscore also has the potential to predict medicine efficacy.
肾透明细胞癌(KIRC)是一种异质性恶性肿瘤,具有高发病率、高转移率和高死亡率。铜稳态失衡可产生细胞毒性并导致细胞损伤。同时,铜还可诱导肿瘤细胞死亡并抑制肿瘤转化。最新研究发现,这种铜诱导的细胞死亡不同于已知的细胞死亡途径,因此将其定义为铜死亡。我们的研究纳入了来自癌症基因组图谱(TCGA)的539例KIRC样本和72例正常组织。在鉴定出与铜死亡显著相关的长链非编码RNA(lncRNA)后,我们根据预后lncRNA对526例KIRC样本进行聚类,得到两种不同模式(铜死亡.C1和C2)。C1表明预后明显更差,具有更高的免疫评分和免疫细胞浸润水平。此外,构建了一个预后特征(CRGscore)以有效且准确地评估KIRC患者的总生存期(OS)。CRGscore定义的组之间在肿瘤免疫微环境(TIME)和肿瘤突变负荷(TMB)方面存在显著差异。CRGscore也具有预测药物疗效的潜力。